 The market-wide sell-off has uncovered countless investment opportunities in the small and mid-cap healthcare arena. I have rediscovered Organogenesis trading at an incredible discount. Organogenesis has relied on PuraPly to accelerate growth while enjoying a diversified revenue stream from their other marketed products. This has led the company to become net positive. 